Sonrotoclax safety study for people with severe liver problems
Treatments studied
This trial tests how a drug called sonrotoclax is processed by the body in people with severe liver impairment compared to people with normal liver function. It aims to check the drug's safety and how it is absorbed, which may help guide dosing for patients with liver issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe liver problems (based on specific blood tests) or have normal liver function.
- Your body mass index (BMI) is between 18 and 42.
- If you are female, you must be surgically sterile or past menopause. If you are male, you must be vasectomized or use effective birth control during the study.
- Your liver condition must be stable (no recent worsening) for at least 4 weeks before starting.
- You must not have had any active infections recently or a history of alcohol or drug abuse in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests how a new drug (AZD4144) is processed by the body in people with different levels of liver function. It aims to see if the drug is safe and how the liver affects its levels, which may help guide future dosing for patients with liver problems.
This trial tests how the body processes quizartinib when the liver is severely impaired. It helps doctors understand if the dose needs to be adjusted for patients with liver issues.
This Phase 1 study measures how tasurgratinib (E7090) and its breakdown product move through the body in people with mild or moderate liver impairment. It aims to understand appropriate dosing and safety considerations for liver impairment.
This early-stage study tests how a new medicine called sonrotoclax is absorbed and processed by your body when taken as a tablet with and without food. Researchers want to understand the best way to take this medicine to help it work effectively.
This study looks at how a new oral drug (called INCB161734) is processed by the body and how safe it is in people with liver problems. It may help doctors understand the right dose for patients with liver impairment.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.